Literature DB >> 21905730

Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.

Oliver Demmer1, Ingrid Dijkgraaf, Udo Schumacher, Luciana Marinelli, Sandro Cosconati, Eleni Gourni, Hans-Jürgen Wester, Horst Kessler.   

Abstract

The chemokine receptor CXCR4 is a critical regulator of inflammation and immune surveillance, and it is specifically implicated in cancer metastasis and HIV-1 infection. On the basis of the observation that several of the known antagonists remarkably share a C(2) symmetry element, we constructed symmetric dimers with excellent antagonistic activity using a derivative of a cyclic pentapeptide as monomer. To optimize the binding affinity, we investigated the influence of the distance between the monomers and the pharmacophoric sites in the synthesized constructs. The affinity studies in combination with docking computations support a two-site binding model. In a final step, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was introduced as chelator for (radio-)metals, thus allowing to exploit these compounds as a new group of CXCR4-binding peptidic probes for molecular imaging and endoradiotherapeutic purposes. Both the DOTA conjugates and some of their corresponding metal complexes retain good CXCR4 affinity, and one (68)Ga labeled compound was studied as PET tracer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21905730     DOI: 10.1021/jm2009716

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  34 in total

Review 1.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

2.  A novel synthetic bivalent ligand to probe chemokine receptor CXCR4 dimerization and inhibit HIV-1 entry.

Authors:  Won-Tak Choi; Santhosh Kumar; Navid Madani; Xiaofeng Han; Shaomin Tian; Chang-Zhi Dong; Dongxiang Liu; Srinivas Duggineni; Jian Yuan; Joseph G Sodroski; Ziwei Huang; Jing An
Journal:  Biochemistry       Date:  2012-08-29       Impact factor: 3.162

Review 3.  Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.

Authors:  T R Nayak; H Hong; Y Zhang; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 4.  Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Authors:  Christopher Kent Arnatt; Yan Zhang
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Al[18F]NOTA-T140 Peptide for Noninvasive Visualization of CXCR4 Expression.

Authors:  Xuefeng Yan; Gang Niu; Zhe Wang; Xiangyu Yang; Dale O Kiesewetter; Orit Jacobson; Baozhong Shen; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

6.  Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents.

Authors:  Ole Tietz; Nazila Kamaly; Graham Smith; Elham Shamsaei; Kishore K Bhakoo; Nicholas J Long; Eric O Aboagye
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-07-10

7.  Determination of the binding mode for the cyclopentapeptide CXCR4 antagonist FC131 using a dual approach of ligand modifications and receptor mutagenesis.

Authors:  S Thiele; J Mungalpara; A Steen; M M Rosenkilde; J Våbenø
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 8.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

9.  Comparison of (18)F-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression.

Authors:  Xiao-Xiang Zhang; Zhongchan Sun; Jinxia Guo; Zhe Wang; Chenxi Wu; Gang Niu; Ying Ma; Dale O Kiesewetter; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

10.  Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction.

Authors:  Rudolf A Werner; Annika Hess; Tobias Koenig; Johanna Diekmann; Thorsten Derlin; Anette Melk; James T Thackeray; Johann Bauersachs; Frank M Bengel
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.